Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    OSI-906-207
Show Display Options
Rank Status Study
1 Completed Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Conditions: Non Small Cell Lung Cancer;   NSCLC
Interventions: Drug: OSI-906;   Drug: Erlotinib;   Drug: Placebo
2 Enrolling by invitation A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Condition: Advanced Solid Tumors
Interventions: Drug: linsitinib;   Drug: erlotinib;   Drug: paclitaxel

Indicates status has not been verified in more than two years